Biosenta Inc (TSE:ZRO)
:ZRO
Top Page
Biosenta Inc
(ZRO)
Select Model
Select Model
Rating:42Neutral
Price Target:
C$0.07
▼(-10.00% Downside)
Action:ReiteratedDate:03/05/26
The score is primarily constrained by weak financial performance (shrinking tiny revenue base, persistent losses, negative equity, and ongoing cash burn). Technicals also remain bearish with the stock below major moving averages, while valuation is difficult to support due to negative earnings and no dividend data.
Positive Factors
Improving free cash flow burn
Free cash flow burn has improved versus 2024, indicating management has taken actions to reduce cash outflows. A sustained reduction in cash burn lengthens runway, lowers near-term refinancing pressure, and provides a structurally stronger footing for executing a turnaround over the next several months.
Negative Factors
Tiny, shrinking revenue base
Revenue is extremely small and declined ~22% YoY, which undermines the company’s ability to achieve scale or cover fixed costs. A contracting top line is a structural headwind: without credible, durable revenue growth the business cannot sustainably absorb operating expenses or fund reinvestment.
Read all positive and negative factors
Positive Factors
Negative Factors
Improving free cash flow burn
Free cash flow burn has improved versus 2024, indicating management has taken actions to reduce cash outflows. A sustained reduction in cash burn lengthens runway, lowers near-term refinancing pressure, and provides a structurally stronger footing for executing a turnaround over the next several months.
Read all positive factors
Biosenta Inc (ZRO) vs. iShares MSCI Canada ETF (EWC)
Market Cap
C$2.61M
Dividend YieldN/A
Average Volume (3M)2.93K
Price to Earnings (P/E)―
Beta (1Y)1.98
Revenue GrowthN/A
EPS GrowthN/A
CountryCA
EmployeesN/A
SectorConsumer Defensive
Sector Strength42
IndustryHousehold & Personal Products
Share Statistics
EPS (TTM)N/A
Shares Outstanding34,768,887
10 Day Avg. Volume5,790
30 Day Avg. Volume2,930
Financial Highlights & Ratios
PEG Ratio0.59
Price to Book (P/B)-0.40
Price to Sales (P/S)3296.23
P/FCF Ratio-8.29
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Biosenta Inc Business Overview & Revenue Model
Company Description
Biosenta Inc. develops, manufactures, and sells anti-microbial chemical compounds for household and industrial applications in Canada. It is involved in developing true, an anti-microbial, dual-action disinfectant that kills viruses, bacteria, mol...
How the Company Makes Money
Biosenta Inc makes money primarily through the sale of its antimicrobial products, which are marketed to a wide range of customers, including individual consumers, businesses, and institutions. The company's revenue model is based on direct sales ...
Biosenta Inc Financial Statement Overview
Summary
Income Statement
6
Very Negative
Balance Sheet
7
Very Negative
Cash Flow
9
Very Negative
| Breakdown | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Sep 2021 |
|---|---|---|---|---|---|
Income Statement | |||||
| Total Revenue | 1.21K | 1.38K | 1.04K | 1.15K | 168.10K |
| Gross Profit | -1.78K | 835.00 | 427.00 | 728.00 | 99.11K |
| EBITDA | -1.39M | -1.09M | -6.24M | -1.24M | -2.03M |
| Net Income | -2.51M | -2.23M | -6.30M | -1.46M | -2.05M |
Balance Sheet | |||||
| Total Assets | 110.33K | 113.54K | 107.59K | 256.08K | 263.66K |
| Cash, Cash Equivalents and Short-Term Investments | 26.49K | 8.53K | 5.88K | 27.26K | 111.88K |
| Total Debt | 694.59K | 5.55M | 5.62M | 94.77K | 152.43K |
| Total Liabilities | 10.17M | 7.99M | 7.96M | 3.18M | 2.86M |
| Stockholders Equity | -10.06M | -7.88M | -7.86M | -2.92M | -2.59M |
Cash Flow | |||||
| Free Cash Flow | -481.24K | -779.35K | -566.35K | -504.43K | -672.29K |
| Operating Cash Flow | -455.38K | -779.35K | -550.79K | -504.43K | -672.29K |
| Investing Cash Flow | -25.86K | 0.00 | -15.56K | 0.00 | 0.00 |
| Financing Cash Flow | 499.20K | 781.99K | 544.97K | 419.81K | 739.86K |
Biosenta Inc Technical Analysis
Negative
0.08
Price Trends
0.08
Negative
0.09
Negative
0.11
Negative
Market Momentum
>-0.01
Negative
31.32
Neutral
33.33
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For TSE:ZRO, the sentiment is Negative. The current price of 0.08 is below the 20-day moving average (MA) of 0.08, below the 50-day MA of 0.08, and below the 200-day MA of 0.11, indicating a bearish trend. The MACD of >-0.01 indicates Negative momentum. The RSI at 31.32 is Neutral, neither overbought nor oversold. The STOCH value of 33.33 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for TSE:ZRO.
Biosenta Inc Peers Comparison
UnderperformOutperform
Sector (62)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
62 Neutral | $20.33B | 14.63 | -3.31% | 3.23% | 1.93% | -12.26% | |
47 Neutral | C$4.33M | -1.22 | -70.53% | ― | -41.18% | 17.65% | |
42 Neutral | C$2.61M | -1.38 | ― | ― | ― | ― | |
41 Neutral | C$1.52M | 1.34 | -129.49% | ― | -98.28% | 76.18% | |
| ― | C$23.26M | -6.90 | -179.43% | ― | ― | -391.89% |
* Consumer Defensive Sector Average
TSE:ZRO
Biosenta Inc
0.08
-0.05
-37.50%
TSE:BGA
BioNeutra Global
0.03
0.00
0.00%
TSE:LFST
Lifeist Wellness
0.04
0.00
0.00%
TSE:PSYC
Psyched Wellness
0.02
0.00
0.00%
TSE:MOOO.X
Happy Supplements Inc.
0.35
-0.73
-67.59%
TSE:URAI
Pure to Pure Beauty Inc.
0.20
0.10
95.00%
Biosenta Inc Corporate Events
Business Operations and StrategyProduct-Related Announcements
Biosenta to Test Antimicrobial Nanoparticles in Alberta Residential Project
Positive
Dec 11, 2025
Biosenta Inc. has entered into a Field Test and Research Agreement with Livespace Homes to evaluate the real-world performance of its antimicrobial nanoparticle technology in a residential construction setting. This initiative aims to generate fie...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.